HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Futura Takes Drug-Free Erectile Dysfunction Gel To Latin America

Executive Summary

UK based Futura Medical has struck a deal with m8 Pharmaceuticals to take its drug-free erectile dysfunction gel to Brazil and Mexico.

You may also be interested in...



Futura Gains EU CE Mark For Drug-Free OTC Erectile Dysfunction Treatment

Futura Medical has received a CE Mark for its MED3000 erectile dysfunction treatment, which combines in gel form a mixture of volatile and non-volatile ingredients.

Over The Counter, 20 Sept 2021: Being A Self-Care 'Source Of Truth' With TheScienceGrad's Natasha Barrow

HBW Insight speaks to regulatory expert and TheScienceGrad founder Natasha Barrow about trust in self-care, and how consumer healthcare companies can become a 'source of truth' in a confusing and misleading world.

GSK Smiles On Corsodyl And Sensodyne Oral Care Brands With Big Budget UK Campaigns

GSK Consumer Healthcare shows Corsodyl and Sensodyne some love with two big budget marketing campaigns in the UK. 

Topics

UsernamePublicRestriction

Register

RS151727

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel